

Inflammatory Bowel Disease and Risk of Ocular Inflammation: A Two-sample Mendelian Randomization Study

Shaojie Ren

Tianjin Medical University Eye Hospital

Manhong xu

Tianjin Medical University Eye Hospital

Wei Shi

Tianjin Medical University General Hospital

Xin Chen

Tianjin Medical University Eye Hospital

Ruiyan Fan

Tianjin Medical University Eye Hospital

Zihao Yu

Tianjin Medical University Eye Hospital

Xiaorong Li (✉ lixiaorong@tmu.edu.cn)

Tianjin Medical University Eye Hospital

Research Article

Keywords: Inflammatory bowel disease, ulcerative colitis, Crohn's disease, ocular Inflammation, Mendelian randomization

Posted Date: March 23rd, 2023

DOI: <https://doi.org/10.21203/rs.3.rs-2657683/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Abstract

Purpose: To determine whether there is a causal effect of inflammatory bowel disease (IBD) on ocular inflammation?

Design: Two-sample Mendelian randomization (MR) study.

Methods: IBD-associated genetic instruments were derived from the largest genome-wide association studies published to date for IBD, ulcerative colitis (UC), and Crohn's diseases (CD). FinnGen research project was used to identify genetic risk variants for conjunctivitis, keratitis, iridocyclitis, chorioretinitis, episcleritis, and optic neuritis. All participants were of European ancestry. Inverse-variance-weighted (IVW) was used as the primary outcome, while weighted median (WM) and MR-Egger were used to improve the estimation of IVW.

Results: A nominal causal effect of genetically predicted IBD on risk of conjunctivitis, keratitis, iridocyclitis, and optic neuritis, but not on chorioretinitis or episcleritis. After Bonferroni correction, the results showed that genetically predicted UC was significantly associated with an increased risk of iridocyclitis (IVW: OR, 1.17; 95% CI, 1.10-1.24, $P=2.54\times 10^{-7}$), CD was significantly associated with conjunctivitis (IVW: OR, 1.05; 95% CI, 1.03-1.08, $P=3.20\times 10^{-5}$), keratitis (IVW: OR, 1.06; 95% CI, 1.02-1.09; $P=1.13\times 10^{-3}$), and iridocyclitis (IVW: OR, 1.09; 95% CI, 1.04-1.14; $P=1.43\times 10^{-4}$).

Conclusion: This study illustrates that IBD causally poses a risk of inflammation of conjunctival, cornea, iris-ciliary and optic neuritis. Moreover, CD is more closely associated with the eye than UC. These implied that the relationship of IBD and different parts of the eye structure were different, and provided novel evidence linking based on the association of the gut-eye axis.

Introduction

Since the concept of the "gut-retina" axis was first proposed, the relationship between gut and eye has attracted great interest in recent years¹. A growing body of research revealed gut dysbiosis may perform a crucial constructive role in the onset and progression of multiple ocular diseases, such as uveitis, diabetic retinopathy². Furthermore, some studies provided perspectives into the presumable pathways forming the gut dysbiosis-ocular surface-lacrimal gland axis³. The link between bowel disease and eye disease needs to be gotten attention in more research.

Inflammatory bowel disease (IBD) which typically includes ulcerative colitis (UC) and Crohn's disease (CD), is a recurrent and immune-mediated inflammatory disorder, characterized by chronic diarrhea, abdominal pain, and perianal bleeding^{4,5}. In recent years, given the natural increase in Western populations, the number of IBD patients in 2030 is likely to exceed 10 million assuming a 1% prevalence, which would be the largest number of IBD patients ever recorded⁶. In addition, symptoms of IBD occur primarily of but are not limited to the gut, and the quality of life for patients with IBD can be substantially

affected by extraintestinal manifestations (EIM)⁷. The existing epidemiological observational studies suggested the link between IBD and ocular inflammation, which may leave irreversible visual impairment and sequelae⁸. Ocular EIM of conjunctivitis and corneal infiltration were first described in two IBD patients as early as 1925⁹. The reported incidence of ocular complications in IBD rates ranges from 3.5–11.8%, usually of inflammatory nature¹⁰. Furthermore, published observational study suggests that conjunctivitis and episcleritis are by far the most common ocular EIM of IBD, and the general incidence of ocular fundus manifestations is low, less than 1% in IBD patients, such as chorioretinitis and optic neuritis^{11,12}. However, observational studies are non-causality, and susceptible to confounding factors, so it is difficult to determine whether this is really the case. It is hoped that the causal relationship between IBD and ocular inflammation needs to be further clarified to up-grading consciousness of ocular EIM, rather than a simple association in observation.

Mendelian randomization (MR) study is a method of causal inference using genetic variants. It relies on the natural random classification of genetic variation during meiosis, and the difference in results between those who carry the variant and those who can't be attributed to differences in risk factors¹³. Due to the non-causality of observational study and the difficulty of randomized controlled trials study¹⁴, MR has become a popular and convenient technique analysis method mainly applied to the etiological inference of epidemiology in recent years, which can imitate RCT^{15,16}.

In this study, we performed a two-sample MR analysis to investigate the causal relationship between IBD and ocular inflammation, using the summary statistics from genome-wide association studies (GWAS) of IBD (including UC and CD) and ocular inflammation (conjunctivitis, keratitis, iridocyclitis, chorioretinitis, episcleritis, and optic neuritis), which were common ocular EIM in previous IBD observational studies.

Methods

Study Design

According to the three key assumptions of MR: (1) The instrumental variables (IVs) is associated with risk factors; (2) IVs is not associated with confounding factors; (3) IVs affects results only through risk factors¹⁷, SNPs representing IVs after screening were selected. Figure 1 shows the flowchart of the two-sample MR study between IBD and ocular inflammation. A nominal causal effect of genetically ($P < 0.05$) was firstly applied to predict IBD on risk of conjunctivitis, keratitis, iridocyclitis, chorioretinitis and episcleritis. Then through Bonferroni correction, a significantly causal effect of genetically, the relationship of UC and CD on increased risk of ocular inflammation, was obtained. In addition, our findings were reported in accordance with MR-STROBE guidelines.

Data sources

IBD-associated SNPs were derived from the largest GWAS published to date for IBD, UC and CD in the European Genome-phenome Archive¹⁸. The statistics came from an extended cohort of 86,640 European

individuals and 9,846 non-Europeans. Although studies showed that majority of the genetic risk were shared across diverse populations, a few loci that showed heterogeneous effects between populations were able to detect^{18,19}. In order to reducing resulting ethnically related bias, our study population's genetic background was restricted to European ancestry. The summary statistics for IBD (N = 12,882 cases, 21,770 controls), UC (N = 6968 cases, 20,464 controls), and CD (N = 5956 cases, 14,927 controls).

FinnGen research project (<https://r5.finngen.fi/>) was used to identify genetic risk variants for conjunctivitis, keratitis, iridocyclitis, episcleritis, chorioretinitis, and optic neuritis. The summary statistics for conjunctivitis (N = 13,655 cases, 203,517 controls), keratitis (N = 5,561 cases, 209,287 controls), iridocyclitis (N = 3,622 cases, 209,287 controls), episcleritis (N = 660 cases, 209,287 controls), chorioretinitis (N = 384 cases, 203,018 controls), and optic neuritis (N = 582 cases, 217,491 controls).

All participants were of European ancestry.

SNP Selection

Firstly, SNPs closely related to IBD were screened from the GWAS data ($P < 5 \times 10^{-8}$) at the genome-wide significance level. To further eliminate linkage disequilibrium, we take clump steps with the "TwoSampleMR" package of the R software, the parameter is set to $R^2 < 0.001$, and < 10000 from the index variant²⁰. Secondly, the SNPs associated with outcome ($P < 5 \times 10^{-6}$) were excluded from retrieving each SNP from outcome GWAS. Meanwhile, palindromic SNPs and SNPs with non-concordant alleles were excluded from the process of harmonizing the IBD and outcome datasets^{21,22}. Thirdly, MR Pleiotropy REsidual Sum and outlier (MR-PRESSO) is used to get rid of potential outliers before each MR Analysis²³. Figure 1 shows the selection criteria and process of the above SNPs.

Mendelian randomization estimates

Three methods which included inverse variance weighting (IVW), weighted median (WM), and MR-Egger regression were performed in this study to estimate the causal association of exposures (IBD, UC, and CD) on risk of outcomes (ocular inflammation). IVW takes the inverse variance of each study as the weight to calculate the weighted average of effect sizes, to summarize the effect sizes of multiple independent studies, which can provide the most precise estimated results when all selected SNPs are valid IVs²⁴. In this study, IVW was used as the primary outcome, while WM and MR-Egger were used to improve the estimation of IVW as they could provide more reliable, albeit less efficient estimates over a wider set of scenarios²⁵⁻²⁸.

Sensitivity analysis

The MR-Egger intercept test was performed to assess the potential pleiotropic effects of the SNPs used as IVs²⁹. If the MR-Egger intercept was statistically significant ($P < 0.05$), the MR analysis was considered to be unreliable. Additionally, to identify potentially influential SNPs, we performed a "leave-one-out" sensitivity analysis to where the MR is performed again but leaving out each SNP in turn. Heterogeneity

of IVs was assessed by Cochran's Q-statistic. A P value of < 0.05 would be regarded as significant heterogeneity. Causal estimates are presented as odds ratios (ORs) with 95% confidence intervals.

Statistical analysis

Before MR analysis, F statistics of these IVs were calculated to determine whether there was a weak IV bias. Respectively, for all IVs, the $F > 10$, the impact of weak IV bias is small, so the selected SNPs can be further used in MR Studies³⁰.

"TwoSampleMR" was used in all statistical analysis software package (<https://github.com/mrcieu/TwoSampleMR>) and "MR-presSO" package (statistical computing internal resistance project) 4.2.0 version in R (version 3.6.1) packages. For a global-level test, a nominally significant two-sided P-value was set as 0.05. For region-level analyses, given the 12 MR estimates, a Bonferroni-corrected P-value was set as $0.05/12$ (4.17×10^{-3}).

Results

Main Results

After excluding outlier SNPs through the MR-PRESSO global test and PhenoScanner, we used the selected SNPs to explore the causal effects of genetically predicted IBD on ocular inflammation (Supplementary Table). Using these SNPs, we performed a comprehensive MR study and identified nominal and significant ocular inflammation influenced by IBD (Fig. 2).

Causal effects of IBD on Ocular Inflammation

The results of MR showed that genetically predicted IBD was associated with an increased risk of conjunctivitis (IVW: OR, 1.05; 95% CI, 0.98–1.12; $P = 1.94 \times 10^{-3}$), keratitis (IVW: OR, 1.05; 95% CI, 1.02–1.08; $P = 6.42 \times 10^{-3}$; MR Egger: OR, 1.05; 95% CI, 0.99–1.12; $P = 7.20 \times 10^{-2}$; WM: OR, 1.05; 95% CI, 1.02–1.10; $P = 9.38 \times 10^{-2}$), iridocyclitis (IVW: OR, 1.18; 95% CI, 1.12–1.24; $P = 6.83 \times 10^{-11}$; MR Egger: OR, 1.19; 95% CI, 1.14–1.45; $P = 9.97 \times 10^{-5}$; WM: OR, 1.19; 95% CI, 1.11–1.29; $P = 5.95 \times 10^{-6}$), optic neuritis (IVW: OR, 1.14; 95% CI, 1.02–1.28; $P = 2.93 \times 10^{-2}$). It can be seen from the scatter plot (Figs. 3A-D) that the causal effect among the three methods is consistent. However, IVW, WM and MR-Egger methods showed no significant association of genetically predicted IBD on episcleritis and chorioretinitis (all $P > 0.05$). More details are shown in Fig. 4.

Causal effects of UC on Ocular Inflammation

The results of the IVW methods showed that genetically predicted UC was associated with an increased risk of keratitis (IVW: OR, 1.05; 95% CI, 1.01–1.10; $P = 1.10 \times 10^{-2}$; MR Egger: OR, 1.11; 95% CI, 1.00–1.22; $P = 5.95 \times 10^{-6}$), iridocyclitis (IVW: OR, 1.17; 95% CI, 1.10–1.24; $P = 2.54 \times 10^{-7}$; WM: OR, 1.18; 95% CI, 1.08–1.28; $P = 2.11 \times 10^{-4}$), optic neuritis (IVW: OR, 1.18; 95% CI, 1.04–1.24; $P = 9.82 \times 10^{-3}$). It can be seen from the scatter plot that the causal effect among the three methods is consistent. It can be seen from the

scatter plot (Figs. 3E-G) that the causal effect among the three methods is consistent. However, IVW, WM and MR-Egger methods showed no significant association of genetically predicted UC on conjunctivitis, episcleritis, or chorioretinitis (all $P > 0.05$). More details are shown in Fig. 4.

Causal effects of CD on Ocular Inflammation

The results of the IVW methods showed that genetically predicted UC was associated with an increased risk of conjunctivitis (IVW: OR, 1.05; 95% CI, 1.03–1.08; $P = 3.20 \times 10^{-5}$; WM: OR, 1.06; 95% CI, 1.02–1.10; $P = 2.57 \times 10^{-3}$), keratitis (IVW: OR, 1.06; 95% CI, 1.02–1.09; $P = 1.13 \times 10^{-3}$), iridocyclitis (IVW: OR, 1.09; 95% CI, 1.04–1.14; $P = 1.43 \times 10^{-4}$; WM: OR, 1.12; 95% CI, 1.05–1.20; $P = 5.05 \times 10^{-4}$), optic neuritis (IVW: OR, 1.11; 95% CI, 0.95–1.32; $P = 4.80 \times 10^{-2}$). It can be seen from the scatter plot that the causal effect among the three methods is consistent. It can be seen from the scatter plot (Figs. 3H-K) that the causal effect among the three methods is consistent. However, IVW, WM and MR-Egger methods showed no significant association of genetically predicted UC on episcleritis, and chorioretinitis (all $P > 0.05$). More details are shown in Fig. 4.

Sensitivity analysis

To further verify the reliability of the above results, we performed pleiotropy, heterogeneity, and sensitivity analysis. No directional pleiotropy was found by MR-Egger regression analysis (Fig. 4). Actually, as we used the random-effects IVW as main result, heterogeneity is acceptable³². Furthermore, no outliers were identified with MR-PRESSO and the leave-one-out plot as well as funnel plots (Supplementary Figure).

Discussion

Main Findings

The main finding of our study is that the UC causally increased the risk of iridocyclitis, and CD causally increased the risk of conjunctivitis, keratitis, and iridocyclitis, whose estimate passed Bonferroni correction. In addition, the estimated effect sizes of UC on conjunctivitis, optic neuritis, and CD on optic neuritis were nominally significant. Given that their IVW-derived $P < 0.05$ without passing Bonferroni correction, these estimates be treated cautiously. On the side, UC did not definitely increase keratitis, and IBD (including UC and CD) did not definitely increase episcleritis, or chorioretinitis, implying that the causal effects of IBD on ocular inflammation at different parts of the eye structure were different.

Results in Context with the Published Literature

Up to 50% of IBD patients experience at least one EIM, whose pathogenic mechanisms are not clearly defined, and unraveling the pathogenic pathways has the potential to enhance our understanding of the pathogenesis not only of EIMs but also of IBD overall³¹. Researchers reported most patients already have diagnosed IBD prior to the development of ocular EIM, and in a minority of cases the ocular disorders precede the diagnosis of IBD^{11,33}. IBD may be active in a majority of patients when ophthalmic inflammation occurs, whose incidence of ocular EIM rates range from 3.5–11.8%^{10,34}. Therefore, the

occurrence of ocular inflammation perhaps becomes the landmark event of the early onset of IBD, contributing to the clinical diagnosis and treatment of IBD and other EIM.

Reports indicate that the ecological dysregulation of gut microbiota (GM) in the human body could trigger the development of inflammatory, metabolic, mental, and immune diseases³⁵. Studies have reported a relationship between and eye diseases³⁶. Another study suggested that dysbacteriosis or clear changes in the healthy gut microbiome may be the decisive event in the occurrence and development of IBD³⁷. In a meta-analysis of IBD that included over 3000 individuals, Mancabelli et al. reported Christensenellaceae as one of five taxa considered a sign of a healthy gut³⁸. In Kangcheng et al. 's MR study on GM in diabetic retinopathy, they surmised that Christensenellaceae and Peptococcaceae might reduce inflammatory damage to the retina through the “intestinal-retinal axis”, thereby affecting disease progression in diabetic retinopathy³⁹. Indeed, Christensenellaceae were consistently depleted in individuals with CD and ulcerative colitis, the two major sub-types of IBD^{40–42}.

Defining the causal relationship and pathogenic pathways in EIMs is challenging due to the lack of consistent criteria for diagnosis and the difficulty in distinguishing drug-induced extraintestinal pathologies from EIMs, including ocular inflammation⁴³. In this study, we performed MR, which was able to rule out these confounding factors to determine the causal relationships between IBD with ocular inflammation. Furthermore, MR study uses open GWAS data, which can save research cost and time, and the data banks were all from European populations, avoiding population bias⁴⁴. Compared with traditional experimental studies, MR simulates a more real random assignment process, the research design is relatively simple, and the research implementation will not violate ethics⁴⁵. On the other hand, the MR analysis prevents confusion and provides a new approach to investigating the “gut-retina” axis mechanisms. Most importantly, it examines the etiological strength of the causal association between IBD and ocular inflammation risk.

The difference between the anterior and posterior segments of eye?

Summary of previous observational studies shows that: the most common eye EIMs is episcleritis, occurring in up to 29% of patients with IBD, and uveitis is less common with a prevalence of 0.5–5.3%, mainly including anterior uveitis, and very severe forms, such as scleritis, posterior or intermediate uveitis are rarer^[46–49]. In our study, we found that IBD (including UC and UD) can cause iridocyclitis (the main inflammation involved in anterior uveitis), but neither can cause chorioretinitis (the main inflammation involved in posterior and intermediate uveitis), which partially supports previous observational studies. However, neither UC nor CD showed a cause-and-effect relationship with episcleritis in our study, which is not consistent with previous observational studies. This difference is first due to the fact that the results of observational epidemiological studies are affected by other relevant factors but not the disease itself, and one of the advantages of MR is that it can exclude such effects. An explanation for EIMs would see them as independent inflammatory events sharing common genetic or environmental risk factors with

IBD^{49,50}. This study suggests that episcleritis in the course of IBD may be a parallel etiology that deserves to be investigated. Due to the high incidence of episcleritis in patients with IBD, external scleritis still needs attention, although there is no causal relationship between IBD and external scleritis.

Ernst et al. reported that the overall incidence of posterior segment manifestations is low, less than 1% in patients with IBD¹². There was a similar trend in our study, and it was found that IBD (including UC and CD) had a nominal causal relationship with optic neuritis and no causal relationship with chorioretinitis. Faruque et al. thought this low incidence of posterior segment manifestations may be also due to the use of systemic steroids in the treatment of IBD and the rapid resolution of posterior segment manifestations with systemic steroids. Therefore, IBD may be somewhat associated with inflammation of the posterior segment of the eye, but it is weaker than the association with the anterior segment, given the causal relationship of IBD on conjunctivitis, keratitis, and iridocyclitis in this study.

The difference between UC and CD?

Usually, it is difficult to establish whether the diagnosis is UC or CD, and it may be several years before the clinical evolution allows a firm decision to be made, because different diseases UC and CD, share many features, including abdominal pain, diarrhea, and rectal bleeding^[11]. Greenstein et al, who recorded a series of 700 patients with IBD, determining the relative incidence and characteristic features of EIM, have shown that ocular EIM is more frequent in CD than UC⁵¹, consistent with other studies⁵²⁻⁵⁴. In this MR analysis assessing the causal link of IBD (including UC and CD) on ocular inflammation, we determined a significant causal effect of genetically predicted CD on conjunctivitis, keratitis, and iridocyclitis, whereas only got a significant causal effect of UC on iridocyclitis. UC nominally influence conjunctivitis but did not definitely influence keratitis. Therefore, CD may be more closely associated with the eye than UC and is more likely to lead to multiple inflammatory diseases of the eye. CD is a systemic disease with a long course, while UC is a mucosal disease of acute onset, often confined to the distal colon. In addition, CD has important immunological differences compared to UC^{54,55}. These differences between the two diseases may be the cause.

Limitations

The study has some limitations. First, it should be noted that the selected GWAS data was all the results of a meta-analysis that had been adjusted for age and sex, and the data for ocular inflammation were all from the Finnish database⁵⁶. Although all the IVs we selected were strong, there is no denying that sample overlap can lead to bias. Secondly, our MR study showed that IBD predicted by genetics had a causal effect on ocular inflammation, but the results of MR Analysis were only genetic evidence. This possible causal relationship and its related mechanisms must be further explored and verified in animal experiments or in population-based observational studies. Thirdly, although the symptoms of ocular inflammation were confined to the eye with subtle or even no effects on gut, we were unable to identify a possible mutual causal relationship between ocular inflammation and IBD due to the lack of an adequate number of IVs for reverse MR analysis.

Conclusions

Our estimates illustrate that IBD causally poses a risk of inflammation of conjunctival, cornea, and iris-ciliary, rather than the posterior segment of eye, which suggests that IBD may have different effects in different eye structures, providing novel evidence linking based on the association of the gut-eye axis. Moreover, IBD showed no cause-and-effect relationship with episcleritis, which is inconsistent with previous observational studies. This difference may be due to the fact that the results of observational epidemiological studies are affected by confounding factors. And CD is more closely associated with the eye than UC, which means UC is more likely to cause multiple inflammation of the eye. Our study is a comprehensive MR analysis that reveals associations between IBD and ocular inflammation and is beneficial to the diagnosis and differentiation of UC and CD. The mechanisms of the association between them should be studied further.

Declarations

Ethics approval and consent to participate

Ethical approval was not sought for this specific project because all data came from the summary statistics of published GWAS, and no individual-level data were used.

Consent for publication

Not applicable.

Availability of data and materials

The datasets analysed during the current study are available in the <https://gwas.mrcieu.ac.uk> and <https://msk.hugeamp.org>.

Competing interests

There are no competing interests for any author.

Funding

Funded by Tianjin Key Medical Discipline (Specialty) Construction Project (TJYXZDXK-037A)

Authors' contributions

Study concept and design: Shaojie Ren and Manhong Xu

Acquisition of data: Shaojie Ren, Manhong Xu, Wei Shi

Analysis or interpretation of data: Shaojie Ren, Wei Shi, Ruiyan Fan, Zihao Yu

Writing of the manuscript: Shaojie Ren, Manhong Xu, and Xin Chen

Critical revision of the manuscript for important intellectual content: Xiaorong Li

Acknowledgements

All authors would like Tianjin Key Laboratory of Retinal Functions and Diseases, Tianjin Branch of National Clinical Research Center for Ocular Disease, Eye Institute and School of Optometry, Tianjin Medical University Eye Hospital.

References

1. Qin X, Zou H, Niu C. The STING pathway: An uncharacterized angle beneath the gut-retina axis. *Exp Eye Res.* 2022;217:108970. doi:10.1016/j.exer.2022.108970
2. Rowan S, Jiang S, Korem T, et al. Involvement of a gut-retina axis in protection against dietary glycemia-induced age-related macular degeneration. *Proc Natl Acad Sci U S A.* 2017;114(22):E4472-E4481. doi:10.1073/pnas.1702302114
3. Moon J, Yoon CH, Choi SH, Kim MK. Can Gut Microbiota Affect Dry Eye Syndrome?. *Int J Mol Sci.* 2020;21(22):8443. Published 2020 Nov 10. doi:10.3390/ijms21228443
4. Khor B, Gardet A, Xavier RJ. Genetics and pathogenesis of inflammatory bowel disease. *Nature.* 2011;474(7351):307-317. doi: 10.1038/nature10209
5. Hodson R. Inflammatory bowel disease. *Nature.* 2016;540(7634):S97. doi:10.1038/540S97a
6. Kaplan GG, Windsor JW. The four epidemiological stages in the global evolution of inflammatory bowel disease. *Nat Rev Gastroenterol Hepatol.* 2021;18(1):56-66. doi:10.1038/s41575-020-00360-x
7. Rogler G, Singh A, Kavanaugh A, Rubin DT. Extraintestinal Manifestations of Inflammatory Bowel Disease: Current Concepts, Treatment, and Implications for Disease Management. *Gastroenterology.* 2021;161(4):1118-1132. doi:10.1053/j.gastro.2021.07.042
8. Trajanoska K, Rivadeneira F. Using Mendelian Randomization to Decipher Mechanisms of Bone Disease. *Curr Osteoporos Rep.* 2018;16(5):531-540. doi:10.1007/s11914-018-0467-3
9. Colia R, Corrado A, Cantatore FP. Rheumatologic and extraintestinal manifestations of inflammatory bowel diseases. *Ann Med.* 2016;48(8):577-585. doi:10.1080/07853890.2016.1195011
10. Ghanchi FD, Rembacken BJ. Inflammatory bowel disease and the eye. *Surv Ophthalmol.* 2003;48(6):663-676. doi:10.1016/j.survophthal.2003.08.004
11. Soukiasian SH, Foster CS, Raizman MB. Treatment strategies for scleritis and uveitis associated with inflammatory bowel disease. *Am J Ophthalmol.* 1994;118(5):601-611. doi:10.1016/s0002-9394(14)76575-4
12. Ernst BB, Lowder CY, Meisler DM, Gutman FA. Posterior segment manifestations of inflammatory bowel disease. *Ophthalmology.* 1991;98(8):1272-1280. doi:10.1016/s0161-6420(91)32143-2

13. Bowden J, Holmes MV. Meta-analysis and Mendelian randomization: A review. *Res Synth Methods*. 2019;10(4):486-496. doi:10.1002/jrsm.1346
14. Schulz KF, Altman DG, Moher D; CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. *BMJ*. 2010;340:c332. Published 2010 Mar 23. doi:10.1136/bmj.c332
15. Kappelmann N, Müller-Myhsok B, Kopf-Beck J. Adapting the randomised controlled trial (RCT) for precision medicine: introducing the nested-precision RCT (npRCT). *Trials*. 2021;22(1):13. Published 2021 Jan 6. doi:10.1186/s13063-020-04965-0
16. Birney E. Mendelian Randomization. *Cold Spring Harb Perspect Med*. 2022;12(4):a041302. Published 2022 May 17. doi:10.1101/cshperspect.a041302
17. Davies NM, Holmes MV, Davey Smith G. Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians. *BMJ*. 2018;362:k601. Published 2018 Jul 12. doi:10.1136/bmj.k601
18. Liu JZ, van Sommeren S, Huang H, et al. Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations. *Nat Genet*. 2015;47(9):979-986. doi:10.1038/ng.3359
19. Okada Y, Wu D, Trynka G, et al. Genetics of rheumatoid arthritis contributes to biology and drug discovery. *Nature*. 2014;506(7488):376-381. doi:10.1038/nature12873
20. Hemani G, Zheng J, Elsworth B, et al. The MR-Base platform supports systematic causal inference across the human phenome. *Elife*. 2018;7:e34408. Published 2018 May 30. doi:10.7554/eLife.34408
21. Hartwig FP, Davies NM, Hemani G, Davey Smith G. Two-sample Mendelian randomization: avoiding the downsides of a powerful, widely applicable but potentially fallible technique. *Int J Epidemiol*. 2016;45(6):1717-1726. doi:10.1093/ije/dyx028
22. Buniello A, MacArthur JAL, Cerezo M, et al. The NHGRI-EBI GWAS Catalog of published genome-wide association studies, targeted arrays and summary statistics 2019. *Nucleic Acids Res*. 2019;47(D1):D1005-D1012. doi:10.1093/nar/gky1120
23. Verbanck M, Chen CY, Neale B, Do R. Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases [published correction appears in *Nat Genet*. 2018 Aug;50(8):1196]. *Nat Genet*. 2018;50(5):693-698. doi:10.1038/s41588-018-0099-7
24. Skrivankova VW, Richmond RC, Woolf BAR, et al. Strengthening the Reporting of Observational Studies in Epidemiology Using Mendelian Randomization: The STROBE-MR Statement. *JAMA*. 2021;326(16):1614-1621. doi:10.1001/jama.2021.18236
25. Lee CH, Cook S, Lee JS, Han B. Comparison of Two Meta-Analysis Methods: Inverse-Variance-Weighted Average and Weighted Sum of Z-Scores. *Genomics Inform*. 2016;14(4):173-180. doi:10.5808/GI.2016.14.4.173
26. Bowden J, Davey Smith G, Haycock PC, Burgess S. Consistent Estimation in Mendelian Randomization with Some Invalid Instruments Using a Weighted Median Estimator. *Genet Epidemiol*.

- 2016;40(4):304-314. doi:10.1002/gepi.21965
27. Chen X, Kong J, Diao X, et al. Depression and prostate cancer risk: A Mendelian randomization study. *Cancer Med*. 2020;9(23):9160-9167. doi:10.1002/cam4.3493
 28. Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. *Int J Epidemiol*. 2015;44(2):512-525. doi:10.1093/ije/dyv080
 29. Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. *Int J Epidemiol*. 2015;44(2):512-525. doi:10.1093/ije/dyv080
 30. John ER, Abrams KR, Brightling CE, Sheehan NA. Assessing causal treatment effect estimation when using large observational datasets. *BMC Med Res Methodol*. 2019;19(1):207. Published 2019 Nov 14. doi:10.1186/s12874-019-0858-x
 31. Vavricka SR, Rogler G, Gantenbein C, et al. Chronological Order of Appearance of Extraintestinal Manifestations Relative to the Time of IBD Diagnosis in the Swiss Inflammatory Bowel Disease Cohort. *Inflamm Bowel Dis*. 2015;21(8):1794-1800. doi:10.1097/MIB.0000000000000429
 32. Burgess S, Davey Smith G, Davies NM, et al. Guidelines for performing Mendelian randomization investigations. *Wellcome Open Res*. 2020;4:186. Published 2020 Apr 28. doi:10.12688/wellcomeopenres.15555.2
 33. Hopkins DJ, Horan E, Burton IL, Clamp SE, de Dombal FT, Goligher JC. Ocular disorders in a series of 332 patients with Crohn's disease. *Br J Ophthalmol*. 1974;58(8):732-737. doi:10.1136/bjo.58.8.732
 34. Fragoulis GE, Liava C, Daoussis D, Akriviadis E, Garyfallos A, Dimitroulas T. Inflammatory bowel diseases and spondyloarthropathies: From pathogenesis to treatment. *World J Gastroenterol*. 2019;25(18):2162-2176. doi:10.3748/wjg.v25.i18.2162
 35. Burcelin R. Gut microbiota and immune crosstalk in metabolic disease. *Mol Metab*. 2016;5(9):771-781. Published 2016 Jun 6. doi:10.1016/j.molmet.2016.05.016
 36. Shivaji S. Connect between gut microbiome and diseases of the human eye. *J Biosci*. 2019;44(5):110.
 37. Hold GL, Smith M, Grange C, Watt ER, El-Omar EM, Mukhopadhyaya I. Role of the gut microbiota in inflammatory bowel disease pathogenesis: what have we learnt in the past 10 years?. *World J Gastroenterol*. 2014;20(5):1192-1210. doi:10.3748/wjg.v20.i5.1192
 38. Mancabelli L, Milani C, Lugli GA, et al. Identification of universal gut microbial biomarkers of common human intestinal diseases by meta-analysis. *FEMS Microbiol Ecol*. 2017;93(12):10.1093/femsec/fix153. doi:10.1093/femsec/fix153
 39. Liu K, Zou J, Fan H, Hu H, You Z. Causal effects of gut microbiota on diabetic retinopathy: A Mendelian randomization study. *Front Immunol*. 2022;13:930318. Published 2022 Sep 8. doi:10.3389/fimmu.2022.930318
 40. Gevers D, Kugathasan S, Denson LA, et al. The treatment-naive microbiome in new-onset Crohn's disease. *Cell Host Microbe*. 2014;15(3):382-392. doi:10.1016/j.chom.2014.02.005

41. Waters JL, Ley RE. The human gut bacteria Christensenellaceae are widespread, heritable, and associated with health. *BMC Biol.* 2019;17(1):83. Published 2019 Oct 28. doi:10.1186/s12915-019-0699-4
42. Kummen M, Holm K, Anmarkrud JA, et al. The gut microbial profile in patients with primary sclerosing cholangitis is distinct from patients with ulcerative colitis without biliary disease and healthy controls. *Gut.* 2017;66(4):611-619. doi:10.1136/gutjnl-2015-310500
43. Hedin CRH, Vavricka SR, Stagg AJ, et al. The Pathogenesis of Extraintestinal Manifestations: Implications for IBD Research, Diagnosis, and Therapy. *J Crohns Colitis.* 2019;13(5):541-554. doi:10.1093/ecco-jcc/jjy191
44. Haworth S, Mitchell R, Corbin L, et al. Apparent latent structure within the UK Biobank sample has implications for epidemiological analysis. *Nat Commun.* 2019;10(1):333. Published 2019 Jan 18. doi:10.1038/s41467-018-08219-1
45. Emdin CA, Khera AV, Kathiresan S. Mendelian Randomization. *JAMA.* 2017;318(19):1925-1926. doi:10.1001/jama.2017.17219
46. Knox DL, Schachat AP, Mustonen E. Primary, secondary and coincidental ocular complications of Crohn's disease. *Ophthalmology.* 1984;91(2):163-173. doi:10.1016/s0161-6420(84)34322-6
47. Vavricka SR, Brun L, Ballabeni P, et al. Frequency and risk factors for extraintestinal manifestations in the Swiss inflammatory bowel disease cohort. *Am J Gastroenterol.* 2011;106(1):110-119. doi:10.1038/ajg.2010.343
48. Lyons JL, Rosenbaum JT. Uveitis associated with inflammatory bowel disease compared with uveitis associated with spondyloarthritis. *Arch Ophthalmol.* 1997;115(1):61-64. doi:10.1001/archophth.1997.01100150063010
49. Parkes M, Cortes A, van Heel DA, Brown MA. Genetic insights into common pathways and complex relationships among immune-mediated diseases. *Nat Rev Genet.* 2013;14(9):661-673. doi:10.1038/nrg3502
50. Severs M, van Erp SJ, van der Valk ME, et al. Smoking is Associated With Extra-intestinal Manifestations in Inflammatory Bowel Disease. *J Crohns Colitis.* 2016;10(4):455-461. doi:10.1093/ecco-jcc/jjv238
51. Greenstein AJ, Janowitz HD, Sachar DB. The extra-intestinal complications of Crohn's disease and ulcerative colitis: a study of 700 patients. *Medicine (Baltimore).* 1976;55(5):401-412. doi:10.1097/00005792-197609000-00004
52. Greuter T, Vavricka SR. Extraintestinal manifestations in inflammatory bowel disease -epidemiology, genetics, and pathogenesis. *Expert Rev Gastroenterol Hepatol.* 2019;13(4):307-317. doi:10.1080/17474124.2019.1574569
53. Vavricka SR, Brun L, Ballabeni P, et al. Frequency and risk factors for extraintestinal manifestations in the Swiss inflammatory bowel disease cohort. *Am J Gastroenterol.* 2011;106(1):110-119. doi:10.1038/ajg.2010.343

54. Zhou T, Pan J, Lai B, et al. Bone mineral density is negatively correlated with ulcerative colitis: a systematic review and meta-analysis. *Clin Transl Med.* 2020;9(1):18. Published 2020 Feb 18. doi:10.1186/s40169-020-00270-0
55. Wu F, Huang Y, Hu J, Shao Z. Mendelian randomization study of inflammatory bowel disease and bone mineral density. *BMC Med.* 2020;18(1):312. Published 2020 Nov 10. doi:10.1186/s12916-020-01778-5
56. Hartwig FP, Borges MC, Horta BL, Bowden J, Davey Smith G. Inflammatory Biomarkers and Risk of Schizophrenia: A 2-Sample Mendelian Randomization Study. *JAMA Psychiatry.* 2017;74(12):1226-1233. doi:10.1001/jamapsychiatry.2017.3191

Figures




Figure 1

Study flow chart of the MR study revealing the causal relationship of IBD on the risk of ocular inflammation.

SNP, single-nucleotide polymorphisms; GWAS, genome-wide association studies; IBD, inflammatory bowel disease; UC, ulcerative colitis; CD, Crohn's disease; LD, linkage disequilibrium; MR-PRESSO, MR Pleiotropy

REsidual Sum and outlier.




Figure 2

Using two-sample MR framework, we reveal that IBD causally influences ocular inflammation, supporting the existence of eye-brain axis.

** P value of IVW estimate $< 4.17 \times 10^{-3}$ is set as significant, represented in solid line whereas < 0.05 is set as nominal significant, represented in dotted line.




Figure 3

Scatter plots for MR analyses of the causal effect of IBD (including UC and CD) on ocular inflammation.

(A) IBD-conjunctivitis (B) IBD-keratitis (C) IBD-iridocyclitis (D) IBD-optic neuritis

(E) UC-keratitis (F) UC-iridocyclitis (G) UC-optic neuritis (H) CD-conjunctivitis

(I) CD-keratitis (J) CD-iridocyclitis (K) CD-optic neuritis




Figure 4

Association of IBD (including UC and CD) on ocular inflammation risk using MR.

SNP, single-nucleotide polymorphism; OR = odds ratio; CI, confidence interval; MR, Mendelian randomization; P(Heterogeneity) , P value for heterogeneity using Cochran Q test; P(Pleiotropy), P value for MR-Egger intercept; IBD, inflammatory bowel disease; UC, ulcerative colitis; CD, Crohn's disease

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [SupplementaryFigure.docx](#)
- [SupplementaryTable.xlsx](#)